Hikma Pharmaceuticals PLC HIK shares shed 3.16% to £19.02 Friday, on what proved to be an all-around rough trading session ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.05% to £19.14 Wednesday, on what proved to be an all-around rough ...

Hikma Pharmaceuticals KSA, announced the expansion of its strategic partnership with the Saudi Gastroenterology Association ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version ...

Hikma Pharmaceuticals (HIK – Research Report) received a Buy rating and a p2,400.00 price target from Berenberg Bank analyst Victoria Lambert yesterday. The company’s shares closed yesterday ...

IBD is a chronic inflammation of the intestine characterised by severe stomach pain and diarrhoea affecting nearly 5 million ...

(Alliance News) - Hikma Pharmaceuticals PLC announced on Tuesday it has completed its acquisition of the US finished dosage form business. Denmark-based Xellia Pharmaceuticals ApS. Xellia's FDF ...

Worldcategory Dechra, Hikma, M&S and Diploma set to join FTSE 100 August 23, 2023 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...